Anbogen, a clinical-stage biotech company, today announced a drug supply collaboration to evaluate the combination of Anbogen's HDAC inhibitor, ABT-301, with BeiGene's anti-PD-1 antibody tislelizumab, ...
Anbogen, a clinical-stage biotech company, today announced a drug supply collaboration to evaluate the combination of Anbogen's HDAC inhibitor, ABT-301 ...
Researchers at the University of Virginia are hard at work trying to understand one of the most pervasive forms of cancer: colorectal. While the overall rate of colon or rectal cancers diagnoses have ...